<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> induces excessive activation of poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase-1 (PARP-1), leading to neuronal cell <z:hpo ids='HP_0011420'>death</z:hpo> and the development of post-ischemic dysfunction </plain></SENT>
<SENT sid="1" pm="."><plain>Blockade of PARP-related signals during <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> has become a focus of interest as a new therapeutic approach for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of the present study was to examine the pharmacological profiles of MP-124, a novel water-soluble PARP-1 inhibitor, and its neuroprotective effects on ischemic injury in vitro and in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>MP-124 demonstrated competitive inhibition of the PARP-1 activity of human recombinant PARP-1 enzyme (Ki=16.5nmol/L) </plain></SENT>
<SENT sid="4" pm="."><plain>In P388D(1) cells, MP-124 inhibited the LDH leakage induced by <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> in a concentration-dependent manner </plain></SENT>
<SENT sid="5" pm="."><plain>(IC(50)=20.8nmol/L) </plain></SENT>
<SENT sid="6" pm="."><plain>In rat primary cortical neurons, MP-124 also inhibited the <z:chebi fb="0" ids="13389">NAD</z:chebi> <z:mpath ids='MPATH_63'>depletion</z:mpath> and polymerized <z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi> formation induced by <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> exposure </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, we investigated the neuroprotective effects of MP-124 in rat permanent and transient <z:hpo ids='HP_0001297'>stroke</z:hpo> models </plain></SENT>
<SENT sid="8" pm="."><plain>In the rat permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) model, MP-124 was administered intravenously for 24h from 5min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of MCAO </plain></SENT>
<SENT sid="9" pm="."><plain>MP-124 (1, 3 and 10mg/kg/h) significantly inhibited the <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> in a dose-dependent manner (18, 42 and 48%) </plain></SENT>
<SENT sid="10" pm="."><plain>In rat transient MCAO model, MP-124 was administered intravenously from 30min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of MCAO </plain></SENT>
<SENT sid="11" pm="."><plain>MP-124 (3 and 10mg/kg/h) significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (53% and 50%) </plain></SENT>
<SENT sid="12" pm="."><plain>The present findings suggest that MP-124 acts as a potent neuroprotective agent in focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and its actions can be attributed to a reduction in <z:chebi fb="0" ids="13389">NAD</z:chebi> <z:mpath ids='MPATH_63'>depletion</z:mpath> and PAR formation </plain></SENT>
</text></document>